8-KEarnings & ResultsExhibits & Filings

BRISTOL MYERS SQUIBB CO 8-K Report, Financial Results (Feb 5, 2018)

Filed February 5, 2018For Securities:BMYCELG-RIBMYMP

Summary

Bristol-Myers Squibb Company (BMY) filed an 8-K on February 5, 2018, to report its financial results for the fourth quarter and full year of 2017. The filing primarily serves to provide investors with access to the official press release and supplemental information detailing these results, which were issued on the same day. Investors should refer to the furnished exhibits, specifically Exhibit 99.1 (the press release) and Exhibit 99.2 (supplemental website information), for the detailed financial performance and operational updates for the periods ended December 31, 2017. While the 8-K itself does not contain the specific financial figures, it officially incorporates by reference the press release where these results are disclosed. Therefore, any analysis of BMY's financial condition and operational results for the specified periods would necessitate a review of the accompanying press release and supplemental materials. This includes key metrics such as revenue, earnings per share, and any forward-looking guidance provided by the company.

Key Highlights

  • 1BMY filed an 8-K on February 5, 2018, to report Q4 and Full Year 2017 financial results.
  • 2The filing incorporates by reference the press release (Exhibit 99.1) detailing the financial results.
  • 3Supplemental financial information is also furnished via Exhibit 99.2 from the company's website.
  • 4Investors are directed to these exhibits for specific financial performance data.
  • 5The event date associated with this filing is February 4, 2018, indicating the results were likely finalized by then.
  • 6This 8-K serves as the official mechanism for disseminating BMY's Q4 and FY 2017 earnings announcement.

Frequently Asked Questions

The primary purpose of this 8-K filing is to officially report and make publicly available Bristol-Myers Squibb's financial results for the fourth quarter and the full twelve months of 2017. It incorporates by reference the press release and supplemental information that contain the detailed financial data.

The actual financial results are not contained within the 8-K filing itself. You will need to refer to Exhibit 99.1, which is the press release issued by Bristol-Myers Squibb on February 5, 2018, and Exhibit 99.2, which is supplemental information posted on their website (www.bms.com).

This report covers the financial results for the fourth quarter of 2017 and the entire twelve-month period of 2017.

This specific 8-K filing (Item 2.02) is focused on financial results. While the press release and supplemental information may contain commentary on operations or strategy in the context of the financial results, the 8-K itself primarily serves to disseminate the earnings announcement. For in-depth strategic updates, other filings or company communications might be more relevant.